Sertraline

Generic Name: Sertraline

Brand Names: Zoloft

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇Cl_₂N

CAS Number: 79617-96-2

Unique Ingredient Identifier: QUC7NX6WMB

Background: Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
...

Indication: Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety di...

Associated Conditions: Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)

Associated Therapies: -

Clinical Trials

Repetitive Behavior Disorders in People With Severe Mental Retardation

Phase 3

Conditions: Mental Retardation
Stereotyped Behavior
Self-Injurious Behavior
Compulsive Behavior

First Posted Date: 2007-06-26

Last Posted Date: 2007-06-26

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registration Number: NCT00491478

Locations: 🇺🇸
Western Carolina Center, Morganton, North Carolina, United States
🇺🇸
Department of Psychiatry, Gainesville, Florida, United States

Combination Therapy in Patients With Depression

Phase 4

Completed

Conditions: Depressive Symptoms

First Posted Date: 2007-06-13

Last Posted Date: 2007-06-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 214

Registration Number: NCT00485862

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

Not Applicable

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2007-01-12

Last Posted Date: 2013-03-22

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 35

Registration Number: NCT00421369

Locations: 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel

Study for Evaluating Different Methods of Measuring Depression Treatment Response

Not Applicable

Completed

Conditions: Depressive Disorder, Major

First Posted Date: 2006-12-04

Last Posted Date: 2008-08-21

Lead Sponsor: Pfizer

Target Recruit Count: 165

Registration Number: NCT00406952

Locations: 🇺🇸
Pfizer Investigational Site, Midvale, Utah, United States

Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder

Phase 4

Terminated

Conditions: Post-Traumatic Stress Disorder

Interventions: Behavioral: Cognitive behavioral therapy (CBT)
Drug: Sertraline

First Posted Date: 2006-10-24

Last Posted Date: 2021-07-21

Lead Sponsor: NYU Langone Health

Target Recruit Count: 39

Registration Number: NCT00391430

Locations: 🇺🇸
NYU Institute for Trauma & Resilience, New York, New York, United States

Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication

Phase 4

Completed

Conditions: Depression

Interventions: Drug: Escitalopram
Drug: Sertraline

First Posted Date: 2006-09-13

Last Posted Date: 2013-02-06

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 118

Registration Number: NCT00375843

Locations: 🇺🇸
UCLA Semel Institute, Los Angeles, California, United States
🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Harvard/MGH, Boston, Massachusetts, United States

Preventing Depression Recurrence in Diabetes

Phase 4

Completed

Conditions: Major Depression
Diabetes

First Posted Date: 2006-09-11

Last Posted Date: 2010-03-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 262

Registration Number: NCT00374426

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Sertraline Pharmacotherapy for Alcoholism Subtypes

Phase 4

Completed

Conditions: Alcoholism

Interventions: Drug: Placebo
Drug: Sertraline

First Posted Date: 2006-08-24

Last Posted Date: 2011-06-21

Lead Sponsor: UConn Health

Target Recruit Count: 134

Registration Number: NCT00368550

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2006-07-13

Last Posted Date: 2011-01-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 494

Registration Number: NCT00351910

Locations: 🇸🇪
Research Site, Uppsala, Sweden

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

Phase 2

Completed

Conditions: Affective Disorders

Interventions: Drug: Sertraline
Drug: Ziprasidone
Drug: Haloperidol

First Posted Date: 2006-06-21

Last Posted Date: 2014-08-19

Lead Sponsor: Duke University

Target Recruit Count: 72

Registration Number: NCT00340379

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇪🇬
Alexandria University, Alexandria, Egypt
🇮🇳
National Institute of Mental Health and Neuroscience, Bangalore, India

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy